-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-0728 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-0728 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-0728 in Breast Cancer Drug Details: TAS-0728 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-2940 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-2940 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-2940 in Solid Tumor Drug Details: TAS-2940 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-114 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-114 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-114 in Metastatic Breast Cancer Drug Details: TAS-114 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAS-2940 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-2940 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-2940 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: TAS-2940...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-2940 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-2940 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-2940 in Non-Small Cell Lung Cancer Drug Details: TAS-2940 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TAS-0728 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-0728 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-0728 in Non-Small Cell Lung Cancer Drug Details: TAS-0728 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAS-0612 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-0612 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-0612 in Solid Tumor Drug Details: TAS-0612 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAS-0612 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAS-0612 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAS-0612...
-
Product Insights
Ta Khoa Project
The Ta Khoa Project is a nickel project in Vietnam. It is currently at the feasibility stage. Empower your strategies with our Ta Khoa Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to...
-
Product Insights
Ta Thang
Ta Thang is a Hydro project located in Lao Cai, Vietnam. The project is currently active. Empower your strategies with our Ta Thang report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire...